PANCREATIC TOXICITY AS AN ADVERSE EFFECT INDUCED BY MEGLUMINE ANTIMONIATE THERAPY IN A CLINICAL TRIAL FOR CUTANEOUS LEISHMANIASIS

LYRA, Marcelo Rosandiski, PASSOS, Sonia Regina Lambert, PIMENTEL, Maria Inês Fernandes, BEDOYA-PACHECO, Sandro Javier, VALETE-ROSALINO, Cláudia Maria, VASCONCELLOS, Erica Camargo Ferreira, ANTONIO, Liliane Fatima, SAHEKI, Mauricio Naoto, SALGUEIRO, Mariza Mattos, SANTOS, Ginelza Peres Lima, RIBEIRO, Madelon Noato, CONCEIÇÃO-SILVA, Fatima, MADEIRA, Maria Fatima, SILVA, Jorge Luiz Nunes, FAGUNDES, Aline, SCHUBACH, Armando Oliveria

PANCREATIC TOXICITY AS AN ADVERSE EFFECT INDUCED BY MEGLUMINE ANTIMONIATE THERAPY IN A CLINICAL TRIAL FOR CUTANEOUS LEISHMANIASIS

AUTOR(ES)

LYRA, Marcelo Rosandiski, PASSOS, Sonia Regina Lambert, PIMENTEL, Maria Inês Fernandes, BEDOYA-PACHECO, Sandro Javier, VALETE-ROSALINO, Cláudia Maria, VASCONCELLOS, Erica Camargo Ferreira, ANTONIO, Liliane Fatima, SAHEKI, Mauricio Naoto, SALGUEIRO, Mariza Mattos, SANTOS, Ginelza Peres Lima, RIBEIRO, Madelon Noato, CONCEIÇÃO-SILVA, Fatima, MADEIRA, Maria Fatima, SILVA, Jorge Luiz Nunes, FAGUNDES, Aline, SCHUBACH, Armando Oliveria

FONTE

Rev. Inst. Med. trop. S. Paulo

DATA DE PUBLICAÇÃO

22/09/2016

RESUMO

SUMMARY American tegumentary leishmaniasis is an infectious disease caused by a protozoan of the genus Leishmania. Pentavalent antimonials are the first choice drugs for cutaneous leishmaniasis (CL), although doses are controversial. In a clinical trial for CL we investigated the occurrence of pancreatic toxicity with different schedules of treatment with meglumine antimoniate (MA). Seventy-two patients were allocated in two different therapeutic groups: 20 or 5 mg of pentavalent antimony (Sb5+)/kg/day for 20 or 30 days, respectively. Looking for adverse effects, patients were asked about abdominal pain, nausea, vomiting or anorexia in each medical visit. We performed physical examinations and collected blood to evaluate serum amylase and lipase in the pre-treatment period, and every 10 days during treatment and one month post-treatment. Hyperlipasemia occurred in 54.8% and hyperamylasemia in 19.4% patients. Patients treated with MA 20 mg Sb5+ presented a higher risk of hyperlipasemia (p = 0.023). Besides, higher MA doses were associated with a 2.05 higher risk ratio (p = 0.003) of developing more serious (moderate to severe) hyperlipasemia. The attributable fraction was 51% in this group. Thirty-six patients presented abdominal pain, nausea, vomiting or anorexia but only 47.2% of those had hyperlipasemia and/ or hyperamylasemia. These findings suggest the importance of the search for less toxic therapeutic regimens for the treatment of CL.